_id
69105436ccc777a4e85d5566
Ticker
CRBU
Name
Caribou Biosciences Inc
Exchange
NASDAQ
Address
2929 7th Street, Berkeley, CA, United States, 94710
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://cariboubio.com
Description
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and autoimmune diseases in the United States and internationally. The company's lead product candidate include CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma, refractory systemic lupus erythematosus, lupus nephritis, and extrarenal lupus. It also develops CB-011, an anti-BCMA allogeneic CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
Last Close
1.86
Volume
406966
Current Price
1.79
Change
-3.7634408602150566
Last Updated
2025-11-29T11:49:28.835Z
Image
-
Ipo Date
2021-07-23T00:00:00.000Z
Market Cap
181328000
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
0.86825
Sentiment Sources
4
Rating
4.3333
Target Price
11.125
Strong Buy
5
Buy
2
Hold
2
Sell
0
Strong Sell
0
Current Quarter
2025-09-30
Revenue
2198000
Cost Of Revenue
631000
Gross Profit
1567000
Operating Expenses
30967000
Operating Income
-29400000
Interest Expense
-
Pretax Income
-27548000
Net Income
-27548000
Eps
-0.29528443470400745
Dividends Per Share
-
Shares Outstanding
93468038
Income Tax Expense
-
EBITDA
-26917000
Operating Margin
-1337.5796178343949
Total Other Income Expense Net
1852000
Cash
11144000
Short Term Investments
136115000
Receivables
2070000
Inventories
-
Total Current Assets
155506000
Property Plant Equipment
23602000
Total Assets
194984000
Payables
3804000
Short Term Debt
2687000
Long Term Debt
-
Total Liabilities
53139000
Equity
141845000
Depreciation
631000
Change In Working Capital
-1409000
Cash From Operations
-25185000
Capital Expenditures
115000
Cash From Investing
10851000
Cash From Financing
277000
Net Change In Cash
-14057000
PE
-
PB
1.1773037273784765
ROE
-19.421199196305828
ROA
-14.128338735485988
FCF
-25300000
Fcf Percent
-11.510464058234758
Piotroski FScore
1
Health Score
35
Deep Value Investing Score
4
Defensive Investing Score
7
Dividend Investing Score
1.5
Economic Moat Investing Score
3.8
Garp Investing Score
2.5
Growth Investing Score
1
Momentum Investing Score
2.5
Net Net Investing Score
2.5
Quality Investing Score
2.5
Value Investing Score
4.5
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
2198000
Quarters > 0 > income Statement > cost Of Revenue
631000
Quarters > 0 > income Statement > gross Profit
1567000
Quarters > 0 > income Statement > operating Expenses
30967000
Quarters > 0 > income Statement > operating Income
-29400000
Quarters > 0 > income Statement > interest Expense
-
Quarters > 0 > income Statement > pretax Income
-27548000
Quarters > 0 > income Statement > net Income
-27548000
Quarters > 0 > income Statement > eps
-0.29528443470400745
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
93293099
Quarters > 0 > income Statement > income Tax Expense
-
Quarters > 0 > income Statement > EBITDA
-26917000
Quarters > 0 > income Statement > operating Margin
-1337.5796178343949
Quarters > 0 > income Statement > total Other Income Expense Net
1852000
Quarters > 0 > balance Sheet > cash
11144000
Quarters > 0 > balance Sheet > short Term Investments
136115000
Quarters > 0 > balance Sheet > receivables
2070000
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
155506000
Quarters > 0 > balance Sheet > property Plant Equipment
23602000
Quarters > 0 > balance Sheet > total Assets
194984000
Quarters > 0 > balance Sheet > payables
3804000
Quarters > 0 > balance Sheet > short Term Debt
2687000
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
53139000
Quarters > 0 > balance Sheet > equity
141845000
Quarters > 0 > cash Flow > net Income
-27548000
Quarters > 0 > cash Flow > depreciation
631000
Quarters > 0 > cash Flow > change In Working Capital
-1409000
Quarters > 0 > cash Flow > cash From Operations
-25185000
Quarters > 0 > cash Flow > capital Expenditures
115000
Quarters > 0 > cash Flow > cash From Investing
10851000
Quarters > 0 > cash Flow > cash From Financing
277000
Quarters > 0 > cash Flow > net Change In Cash
-14057000
Quarters > 0 > ratios > PE
-0.29528443470400745
Quarters > 0 > ratios > PB
1.1773037273784765
Quarters > 0 > ratios > ROE
-19.421199196305828
Quarters > 0 > ratios > ROA
-14.128338735485988
Quarters > 0 > ratios > FCF
-25300000
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-11.510464058234758
Quarters > 0 > health Score
35
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
2667000
Quarters > 1 > income Statement > cost Of Revenue
-
Quarters > 1 > income Statement > gross Profit
2667000
Quarters > 1 > income Statement > operating Expenses
50245000
Quarters > 1 > income Statement > operating Income
-47578000
Quarters > 1 > income Statement > interest Expense
-
Quarters > 1 > income Statement > pretax Income
-54098000
Quarters > 1 > income Statement > net Income
-54098000
Quarters > 1 > income Statement > eps
-0.5815194790751559
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
93028698
Quarters > 1 > income Statement > income Tax Expense
-
Quarters > 1 > income Statement > EBITDA
-34261000
Quarters > 1 > income Statement > operating Margin
-1783.95200599925
Quarters > 1 > income Statement > total Other Income Expense Net
-6520000
Quarters > 1 > balance Sheet > cash
25201000
Quarters > 1 > balance Sheet > short Term Investments
158747000
Quarters > 1 > balance Sheet > receivables
2780000
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
192506000
Quarters > 1 > balance Sheet > property Plant Equipment
24640000
Quarters > 1 > balance Sheet > total Assets
220903000
Quarters > 1 > balance Sheet > payables
3243000
Quarters > 1 > balance Sheet > short Term Debt
2287000
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
54771000
Quarters > 1 > balance Sheet > equity
166132000
Quarters > 1 > cash Flow > net Income
-54098000
Quarters > 1 > cash Flow > depreciation
1167000
Quarters > 1 > cash Flow > change In Working Capital
554000
Quarters > 1 > cash Flow > cash From Operations
-28258000
Quarters > 1 > cash Flow > capital Expenditures
418000
Quarters > 1 > cash Flow > cash From Investing
24036000
Quarters > 1 > cash Flow > cash From Financing
6000
Quarters > 1 > cash Flow > net Change In Cash
-4216000
Quarters > 1 > ratios > PE
-0.5815194790751559
Quarters > 1 > ratios > PB
1.0023437352225941
Quarters > 1 > ratios > ROE
-32.56326294753569
Quarters > 1 > ratios > ROA
-24.48948180875769
Quarters > 1 > ratios > FCF
-28676000
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-10.752155980502437
Quarters > 1 > health Score
35
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
2353000
Quarters > 2 > income Statement > cost Of Revenue
-
Quarters > 2 > income Statement > gross Profit
2353000
Quarters > 2 > income Statement > operating Expenses
45266000
Quarters > 2 > income Statement > operating Income
-42913000
Quarters > 2 > income Statement > interest Expense
-
Quarters > 2 > income Statement > pretax Income
-39991000
Quarters > 2 > income Statement > net Income
-39991000
Quarters > 2 > income Statement > eps
-0.4314978287591625
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
92679493
Quarters > 2 > income Statement > income Tax Expense
-
Quarters > 2 > income Statement > EBITDA
-41748000
Quarters > 2 > income Statement > operating Margin
-1823.756906077348
Quarters > 2 > income Statement > total Other Income Expense Net
2922000
Quarters > 2 > balance Sheet > cash
29417000
Quarters > 2 > balance Sheet > short Term Investments
179048000
Quarters > 2 > balance Sheet > receivables
2740000
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
217323000
Quarters > 2 > balance Sheet > property Plant Equipment
38039000
Quarters > 2 > balance Sheet > total Assets
273656000
Quarters > 2 > balance Sheet > payables
3873000
Quarters > 2 > balance Sheet > short Term Debt
1901000
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
56434000
Quarters > 2 > balance Sheet > equity
217222000
Quarters > 2 > cash Flow > net Income
-39991000
Quarters > 2 > cash Flow > depreciation
1165000
Quarters > 2 > cash Flow > change In Working Capital
-1496000
Quarters > 2 > cash Flow > cash From Operations
-36725000
Quarters > 2 > cash Flow > capital Expenditures
1042000
Quarters > 2 > cash Flow > cash From Investing
49381000
Quarters > 2 > cash Flow > cash From Financing
468000
Quarters > 2 > cash Flow > net Change In Cash
13124000
Quarters > 2 > ratios > PE
-0.4314978287591625
Quarters > 2 > ratios > PB
0.7637177287291342
Quarters > 2 > ratios > ROE
-18.410197862095
Quarters > 2 > ratios > ROA
-14.613602479024761
Quarters > 2 > ratios > FCF
-37767000
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-16.05057373565661
Quarters > 2 > health Score
34
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
2077000
Quarters > 3 > income Statement > cost Of Revenue
29864000
Quarters > 3 > income Statement > gross Profit
-27787000
Quarters > 3 > income Statement > operating Expenses
11088000
Quarters > 3 > income Statement > operating Income
-38875000
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
-35499000
Quarters > 3 > income Statement > net Income
-35490000
Quarters > 3 > income Statement > eps
-0.3929452542227913
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
90317925
Quarters > 3 > income Statement > income Tax Expense
-9000
Quarters > 3 > income Statement > EBITDA
-37091000
Quarters > 3 > income Statement > operating Margin
-1871.6899374097256
Quarters > 3 > income Statement > total Other Income Expense Net
3376000
Quarters > 3 > balance Sheet > cash
16293000
Quarters > 3 > balance Sheet > short Term Investments
193244000
Quarters > 3 > balance Sheet > receivables
3251000
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
219377000
Quarters > 3 > balance Sheet > property Plant Equipment
39290000
Quarters > 3 > balance Sheet > total Assets
313313000
Quarters > 3 > balance Sheet > payables
2476000
Quarters > 3 > balance Sheet > short Term Debt
1426000
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
60362000
Quarters > 3 > balance Sheet > equity
252951000
Quarters > 3 > cash Flow > net Income
-35490000
Quarters > 3 > cash Flow > depreciation
1184000
Quarters > 3 > cash Flow > change In Working Capital
-4302000
Quarters > 3 > cash Flow > cash From Operations
-35470000
Quarters > 3 > cash Flow > capital Expenditures
518000
Quarters > 3 > cash Flow > cash From Investing
15930000
Quarters > 3 > cash Flow > cash From Financing
3863000
Quarters > 3 > cash Flow > net Change In Cash
-15677000
Quarters > 3 > ratios > PE
-0.3929452542227913
Quarters > 3 > ratios > PB
0.6391320285351708
Quarters > 3 > ratios > ROE
-14.030385331546427
Quarters > 3 > ratios > ROA
-11.327330816148708
Quarters > 3 > ratios > FCF
-35988000
Quarters > 3 > ratios > Piotroski FScore
1
Quarters > 3 > ratios > fcf Percent
-17.32691381800674
Quarters > 3 > health Score
34
Valuation > metrics > PE
-0.29528443470400745
Valuation > metrics > PB
1.1773037273784765
Valuation > final Score
80
Valuation > verdict
Fair
Profitability > metrics > ROE
-19.421199196305828
Profitability > metrics > ROA
-17.715072087250654
Profitability > metrics > Net Margin
-12.533212010919017
Profitability > final Score
0
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.3746272339525538
Risk > metrics > Interest Coverage
-46.59270998415214
Risk > final Score
-126
Risk > verdict
High
Liquidity > metrics > Current Ratio
23.95717146818672
Liquidity > metrics > Quick Ratio
23.95717146818672
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
80
Prev Valuations > 1
70
Prev Valuations > 2
70
Prev Profitabilities > 0
0
Prev Profitabilities > 1
0
Prev Profitabilities > 2
0
Prev Risks > 0
50
Prev Risks > 1
-38
Prev Risks > 2
-38
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2025-12-14T00:21:44.728Z
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and autoimmune diseases in the United States and internationally. The company's lead product candidate include CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma, refractory systemic lupus erythematosus, lupus nephritis, and extrarenal lupus. It also develops CB-011, an anti-BCMA allogeneic CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
Stock Price
$ 0.00
0% decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/ACaribou Biosciences Target of Unusually Large Options Trading (NASDAQ:CRBU) MarketBeat
Read more →Caribou Biosciences, Inc. $CRBU Shares Bought by Envestnet Asset Management Inc. - MarketBeat
11/28/2025
Caribou Biosciences, Inc. $CRBU Shares Bought by Envestnet Asset Management Inc. MarketBeat
Read more →Showing 2 of 10
(Last Updated 2025-09-30)
Rating:
BUY
Target Price:
$11.125
Analyst Picks
Strong Buy
5
Buy
2
Hold
2
Sell
0
Strong Sell
0
Sentiment:
Bullish
(Last Updated 2025-09-30)
Health Score
Price to Book Ratio (P/B)
-
Very Low
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very Low
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Very High
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 45.26% of the total shares of Caribou Biosciences Inc
1.
Pfizer Inc(5.0368%)
since
2025/06/30
2.
Vanguard Group Inc(4.3919%)
since
2025/06/30
3.
Kynam Capital Management, LP(3.2943%)
since
2025/06/30
4.
Vanguard Total Stock Mkt Idx Inv(2.8388%)
since
2025/07/31
5.
Schonfeld Strategic Advisors LLC(2.4407%)
since
2025/06/30
6.
ACATIS Datini Valueflex Fonds A(2.1477%)
since
2025/07/31
7.
BlackRock Inc(2.0226%)
since
2025/06/30
8.
Millennium Management LLC(1.6651%)
since
2025/06/30
9.
Selectra J. Lamarck Biotech A(1.6108%)
since
2025/08/31
10.
Two Sigma Advisers, LLC(1.5547%)
since
2025/06/30
11.
abrdn Life Sciences Investors(1.4915%)
since
2025/08/31
12.
Partner Fund Management LP(1.4592%)
since
2025/06/30
13.
Dimensional Fund Advisors, Inc.(1.4039%)
since
2025/06/30
14.
Geode Capital Management, LLC(1.0534%)
since
2025/06/30
15.
Jacobs Levy Equity Management, Inc.(1.0276%)
since
2025/06/30
16.
Two Sigma Investments LLC(0.9971%)
since
2025/06/30
17.
Aberdeen Group PLC(0.9639%)
since
2025/06/30
18.
Vanguard Institutional Extnd Mkt Idx Tr(0.9499%)
since
2025/07/31
19.
Bank of America Corp(0.8686%)
since
2025/06/30
20.
Goldman Sachs Group Inc(0.8501%)
since
2025/06/30
21.
Pale Fire Capital SE(0.8323%)
since
2025/06/30
22.
FMR Inc(0.7833%)
since
2025/06/30
23.
Maverick Capital Ltd(0.7007%)
since
2025/06/30
24.
AQR Capital Management LLC(0.6949%)
since
2025/06/30
25.
Royal Bank of Canada(0.6435%)
since
2025/06/30
26.
Fidelity Extended Market Index(0.5162%)
since
2025/07/31
27.
Schwab US Small-Cap ETFâ„¢(0.4336%)
since
2025/08/30
28.
DFA US Targeted Value I(0.4151%)
since
2025/07/31
29.
Dimensional US Targeted Value ETF(0.3324%)
since
2025/08/29
30.
Bruce(0.2685%)
since
2025/06/30
31.
AXS Green Alpha ETF(0.2261%)
since
2025/08/29
32.
Goldman Sachs Small Cp Val Insghts Instl(0.2139%)
since
2025/04/30
33.
Extended Equity Market Fund K(0.1879%)
since
2025/06/30
34.
Fidelity Total Market Index(0.1612%)
since
2025/07/31
35.
Bridgeway Ultra-Small Company Market(0.1396%)
since
2025/06/30
36.
Multi-Manager Small Cap Eq Strat Inst(0.1375%)
since
2025/07/31
37.
Galileo - Biotech Innovation Fund S USD(0.1356%)
since
2025/02/28
38.
Fidelity Series Total Market Index(0.1316%)
since
2025/07/31
39.
Dimensional US Core Equity 2 ETF(0.1212%)
since
2025/08/29
40.
Spartan Extended Market Index Pool F(0.1147%)
since
2025/07/31
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
No earnings data available.
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.